Website:www.dcchemicals.

com
Email: info@dcchemicals.com Phone:+86-21-58447131
Marketing Center: Room 610,Building 15, Jinxiang Rd 201, Shanghai,
China

Datasheet of Arg-Gly-Asp-Ser

Description:
Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic
inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines,
iNOS and MMP-9. in vitro: The RGDS-modified surface caused up-regulation of alpha(v)beta(3) integrin.Attachment to the
RGDS-treated membrane completely abolished apoptosis induced by staurosporine, the Ca(2+).P(i) ion pair, and sodium
nitroprusside. A pretreatment with RGDS inhibited LPS-induced increases in neutrophil and macrophage numbers, total protein
levels and TNF-alpha and MIP-2 levels, and matrix metalloproteinase-9 activity in bronchoalveolar lavage (BAL) fluid at 4 or 24
h post-LPS treatment. RGDS inhibited LPS-induced phosphorylation of focal adhesion kinase and MAP kinases, including ERK,
JNK, and p38 MAP kinase, in lung tissue. RGDS interacts with survivin, as well as with procaspase-3, -8 and -9. RGDS-peptide
binding to survivin was found to be specific, at high affinity (Kd 27.5 muM) and located at the survivin C-terminus.
RGDS-survivin interaction appeared to play a key role, since RGDS lost its anti-mitogenic effect in survivin-deprived cells with
a specific siRNA. in vivo: Synthetic RGDS peptide was given intraperitoneally 30 min before LPS/D-GalN injection. Liver
function and the extent of liver injury were analyzed biochemically and pathologically respectively. Pretreatment with synthetic
RGDS peptide significantly improved LPS/D-GalN-induced mortality, and liver injury as determined by alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) activities, as well as pathological analysis. In addition, RGDS
peptide significantly reduced tumor necrosis factor (TNF)- and macrophage inflammatory protein (MIP)-2 production, and
decreased myeloperoxidase (MPO) and NF-B activity. In eyes with injections of 300 or 100 microg of RGDS peptide on the
14th day after laser photocoagulation, the development of CNV was significantly (P < 0.01) inhibited showing by
RPE-choroid-sclera flat mounts. Histologically, the thickness of the CNV lesions was significantly (P < 0.01) reduced in eyes that
received 300 or 100 microg of RGDS peptide injection.

Chemical Information
Catalog

DC9487

Purity of current batch:

>98%

Molecular Weight (MW)

433.42

Molecular Formula

C15H27N7O8

CAS No.

91037-65-9

Solubility (25C)

DMSO

Storage

Store at -20C (desiccating conditions).

Handling:
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in
advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable
for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room
temperature for at least 1 hour.